 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ERYTHROMYCIN ETHYLSUCCINATE increase or [0m
[34mdecrease the risk of myocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ERYTHROMYCIN ETHYLSUCCINATE increase or [0m
[32mdecrease the risk of myocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ERYTHROMYCIN ETHYLSUCCINATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: references: REFERENCES Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart [0m
[31mAssociation: Prevention of Rheumatic Fever. Circulation. [0m[1;31m78[0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m:[0m[1;31m1082[0m[31m-[0m[1;31m1086[0m[31m, October [0m[1;31m1988[0m[31m. Honein, M.A., et al.: Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a [0m
[31mcase review and cohort study. ERYTHROMYCIN ETHYLSUCCINATE: references: The Lancet [0m[1;31m1999[0m[31m;[0m[1;31m354[0m[31m [0m[1;31m([0m[1;31m9196[0m[1;31m)[0m[31m: [0m[1;31m2101[0m[31m-[0m[1;31m5[0m[31m         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: information_for_patients: Information for Patients Patients should be counseled that antibacterial drugs including Ery-Ped should only be used to treat bacterial [0m
[31minfections. They do not treat viral infections [0m[1;31m([0m[31me.g., the common cold[0m[1;31m)[0m[31m. When Ery-Ped is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better [0m
[31mearly in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m decrease the effectiveness of the immediate [0m
[31mtreatment and [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m increase the likelihood that bacteria will develop resistance and will not be treatable by Ery-Ped or other antibacterial drugs in the future. Diarrhea is a common problem caused by [0m
[31mantibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools [0m[1;31m([0m[31mwith or without stomach cramps [0m
[31mand fever[0m[1;31m)[0m[31m even as late as two or more months after having taken the last dose of the antibiotic. ERYTHROMYCIN ETHYLSUCCINATE: information_for_patients: If this occurs, patients should contact their [0m
[31mphysician as soon as possible.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: brand_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: precautions: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased [0m
[31manticoagulation effects due to interactions of erythromycin with various oral anticoagulants may be more pronounced in the elderly. Erythromycin is a substrate and inhibitor of the 3A isoform [0m
[31msubfamily of the cytochrome p450 enzyme system [0m[1;31m([0m[31mCYP3A[0m[1;31m)[0m[31m. Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could [0m
[31mincrease or prolong both the therapeutic and adverse effects of the concomitant drug. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by [0m
[31mCYP3A should be monitored closely in patients concurrently receiving erythromycin. The following are examples of some clinically significant CYP3A based drug interactions. ERYTHROMYCIN ETHYLSUCCINATE:[0m
[31mprecautions: Interactions with other drugs metabolized by the CYP3A isoform are also possible. The following CYP3A based drug interactions have been observed with erythromycin products in [0m
[31mpost-marketing experience: Ergotamine/dihydroergotamine Post-marketing reports indicate that co-administration of erythromycin with ergotamine or dihydroergotamine has been associated with acute ergot[0m
[31mtoxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system. Concomitant administration of erythromycin with ergotamine or [0m
[31mdihydroergotamine is contraindicated [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. ERYTHROMYCIN ETHYLSUCCINATE: precautions: Triazolobenzodiazepines [0m[1;31m([0m[31msuch as triazolam and alprazolam[0m[1;31m)[0m[31m and Related Benzodiazepines [0m
[31mErythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines. HMG-CoA Reductase Inhibitors Erythromycin[0m
[31mhas been reported to increase concentrations of HMG-CoA reductase inhibitors [0m[1;31m([0m[31me.g., lovastatin and simvastatin[0m[1;31m)[0m[31m. Rare reports of rhabdomyolysis have been reported in patients taking these drugs [0m
[31mconcomitantly. Sildenafil [0m[1;31m([0m[31mViagra[0m[1;31m)[0m[31m Erythromycin has been reported to increase the systemic exposure [0m[1;31m([0m[31mAUC[0m[1;31m)[0m[31m of sildenafil. Reduction of sildenafil dosage should be considered. [0m[1;31m([0m[31mSee Viagra package [0m
[31minsert. ERYTHROMYCIN ETHYLSUCCINATE: precautions: There have been spontaneous or published reports of CYP3A based interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil,[0m
[31mdisopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine, and bromocriptine. Concomitant administration of erythromycin with cisapride, pimozide, astemizole, or terfenadine is [0m
[31mcontraindicated. [0m[1;31m([0m[31mSee CONTRAINDICATIONS .[0m[1;31m)[0m[31m In addition, there have been reports of interactions of erythromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, [0m
[31mand valproate. ERYTHROMYCIN ETHYLSUCCINATE: precautions: Erythromycin has been reported to significantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken [0m
[31mconcomitantly. Rare cases of serious cardiovascular adverse events, including electrocardiographic QT/QT c interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias[0m
[31mhave been observed. [0m[1;31m([0m[31mSee CONTRAINDICATIONS .[0m[1;31m)[0m[31m In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin. There have been post-marketing reports of [0m
[31mdrug interactions when erythromycin was co-administered with cisapride, resulting in QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, and torsades de pointes [0m
[31mmost likely due to the inhibition of hepatic metabolism of cisapride by erythromycin. Fatalities have been reported.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: Drug Interactions Theophylline Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in [0m
[31mserum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient [0m
[31mis receiving concomitant erythromycin therapy. There have been published reports suggesting that when oral erythromycin is given concurrently with theophylline there is a decrease in erythromycin [0m
[31mserum concentrations of approximately [0m[1;31m35[0m[31m%. The mechanism by which this interaction occurs is unknown. The decrease in erythromycin concentrations due to co-administration of theophylline could result [0m
[31min subtherapeutic concentrations of erythromycin. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent[0m
[31mverapamil, belonging to the calcium channel blockers drug class. Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels. There have been [0m
[31mreports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to interactions of erythromycin with various oral [0m
[31manticoagulants may be more pronounced in the elderly. Erythromycin is a substrate and inhibitor of the 3A isoform subfamily of the cytochrome p450 enzyme system [0m[1;31m([0m[31mCYP3A[0m[1;31m)[0m[31m. ERYTHROMYCIN ETHYLSUCCINATE: [0m
[31mdrug_interactions: Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the [0m
[31mtherapeutic and adverse effects of the concomitant drug. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored [0m
[31mclosely in patients concurrently receiving erythromycin. The following are examples of some clinically significant CYP3A based drug interactions. Interactions with other drugs metabolized by the CYP3A[0m
[31misoform are also possible. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: The following CYP3A based drug interactions have been observed with erythromycin products in post-marketing experience: [0m
[31mErgotamine/dihydroergotamine Post-marketing reports indicate that co-administration of erythromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by [0m
[31mvasospasm and ischemia of the extremities and other tissues including the central nervous system. Concomitant administration of erythromycin with ergotamine or dihydroergotamine is contraindicated [0m
[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. Triazolobenzodiazepines [0m[1;31m([0m[31msuch as triazolam and alprazolam[0m[1;31m)[0m[31m and Related Benzodiazepines Erythromycin has been reported to decrease the clearance of triazolam and midazolam, [0m
[31mand thus, may increase the pharmacologic effect of these benzodiazepines. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: HMG-CoA Reductase Inhibitors Erythromycin has been reported to increase [0m
[31mconcentrations of HMG-CoA reductase inhibitors [0m[1;31m([0m[31me.g., lovastatin and simvastatin[0m[1;31m)[0m[31m. Rare reports of rhabdomyolysis have been reported in patients taking these drugs concomitantly. Sildenafil [0m[1;31m([0m[31mViagra[0m[1;31m)[0m[31m [0m
[31mErythromycin has been reported to increase the systemic exposure [0m[1;31m([0m[31mAUC[0m[1;31m)[0m[31m of sildenafil. Reduction of sildenafil dosage should be considered. [0m[1;31m([0m[31mSee Viagra package insert.[0m[1;31m)[0m[31m There have been spontaneous or [0m
[31mpublished reports of CYP3A based interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine,[0m
[31mand bromocriptine. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: Concomitant administration of erythromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated. [0m[1;31m([0m[31mSee [0m
[31mCONTRAINDICATIONS .[0m[1;31m)[0m[31m In addition, there have been reports of interactions of erythromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate. [0m
[31mErythromycin has been reported to significantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse[0m
[31mevents, including electrocardiographic QT/QT c interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias have been observed. [0m[1;31m([0m[31mSee CONTRAINDICATIONS .[0m[1;31m)[0m[31m In addition, [0m
[31mdeaths have been reported rarely with concomitant administration of terfenadine and erythromycin. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: There have been post-marketing reports of drug [0m
[31minteractions when erythromycin was co-administered with cisapride, resulting in QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, and torsades de pointes most [0m
[31mlikely due to the inhibition of hepatic metabolism of cisapride by erythromycin. Fatalities have been reported. [0m[1;31m([0m[31mSee CONTRAINDICATIONS .[0m[1;31m)[0m[31m Colchicine Colchicine is a substrate for both CYP3A4 and the [0m
[31mefflux transporter P-glycoprotein [0m[1;31m([0m[31mP-gp[0m[1;31m)[0m[31m. Erythromycin is considered a moderate inhibitor of CYP3A4. A significant increase in colchicine plasma concentration is anticipated when co-administered with [0m
[31mmoderate CYP3A4 inhibitors such as erythromycin.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"ERYTHROMYCIN ETHYLSUCCINATE"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does ERYTHROMYCIN ETHYLSUCCINATE increase or [0m
[31mdecrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of myocardial infarction?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes ERYTHROMYCIN ETHYLSUCCINATE increase or [0m
[32mdecrease the risk of myocardial infarction?[0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of myocardial infarction?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"filter_drugs"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"ERYTHROMYCIN ETHYLSUCCINATE"[0m
[32m    [0m[1;32m][0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: references: REFERENCES Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart [0m
[31mAssociation: Prevention of Rheumatic Fever. Circulation. [0m[1;31m78[0m[1;31m([0m[1;31m4[0m[1;31m)[0m[31m:[0m[1;31m1082[0m[31m-[0m[1;31m1086[0m[31m, October [0m[1;31m1988[0m[31m. Honein, M.A., et al.: Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a [0m
[31mcase review and cohort study. ERYTHROMYCIN ETHYLSUCCINATE: references: The Lancet [0m[1;31m1999[0m[31m;[0m[1;31m354[0m[31m [0m[1;31m([0m[1;31m9196[0m[1;31m)[0m[31m: [0m[1;31m2101[0m[31m-[0m[1;31m5[0m[31m         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: information_for_patients: Information for Patients Patients should be counseled that antibacterial drugs including Ery-Ped should only be used to treat bacterial [0m
[31minfections. They do not treat viral infections [0m[1;31m([0m[31me.g., the common cold[0m[1;31m)[0m[31m. When Ery-Ped is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better [0m
[31mearly in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may [0m[1;31m([0m[1;31m1[0m[1;31m)[0m[31m decrease the effectiveness of the immediate [0m
[31mtreatment and [0m[1;31m([0m[1;31m2[0m[1;31m)[0m[31m increase the likelihood that bacteria will develop resistance and will not be treatable by Ery-Ped or other antibacterial drugs in the future. Diarrhea is a common problem caused by [0m
[31mantibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools [0m[1;31m([0m[31mwith or without stomach cramps [0m
[31mand fever[0m[1;31m)[0m[31m even as late as two or more months after having taken the last dose of the antibiotic. ERYTHROMYCIN ETHYLSUCCINATE: information_for_patients: If this occurs, patients should contact their [0m
[31mphysician as soon as possible.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: spl_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: product_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: brand_name         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: package_ndc         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: openfda: spl_set_id         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: precautions: There have been reports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased [0m
[31manticoagulation effects due to interactions of erythromycin with various oral anticoagulants may be more pronounced in the elderly. Erythromycin is a substrate and inhibitor of the 3A isoform [0m
[31msubfamily of the cytochrome p450 enzyme system [0m[1;31m([0m[31mCYP3A[0m[1;31m)[0m[31m. Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could [0m
[31mincrease or prolong both the therapeutic and adverse effects of the concomitant drug. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by [0m
[31mCYP3A should be monitored closely in patients concurrently receiving erythromycin. The following are examples of some clinically significant CYP3A based drug interactions. ERYTHROMYCIN ETHYLSUCCINATE:[0m
[31mprecautions: Interactions with other drugs metabolized by the CYP3A isoform are also possible. The following CYP3A based drug interactions have been observed with erythromycin products in [0m
[31mpost-marketing experience: Ergotamine/dihydroergotamine Post-marketing reports indicate that co-administration of erythromycin with ergotamine or dihydroergotamine has been associated with acute ergot[0m
[31mtoxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system. Concomitant administration of erythromycin with ergotamine or [0m
[31mdihydroergotamine is contraindicated [0m[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. ERYTHROMYCIN ETHYLSUCCINATE: precautions: Triazolobenzodiazepines [0m[1;31m([0m[31msuch as triazolam and alprazolam[0m[1;31m)[0m[31m and Related Benzodiazepines [0m
[31mErythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacologic effect of these benzodiazepines. HMG-CoA Reductase Inhibitors Erythromycin[0m
[31mhas been reported to increase concentrations of HMG-CoA reductase inhibitors [0m[1;31m([0m[31me.g., lovastatin and simvastatin[0m[1;31m)[0m[31m. Rare reports of rhabdomyolysis have been reported in patients taking these drugs [0m
[31mconcomitantly. Sildenafil [0m[1;31m([0m[31mViagra[0m[1;31m)[0m[31m Erythromycin has been reported to increase the systemic exposure [0m[1;31m([0m[31mAUC[0m[1;31m)[0m[31m of sildenafil. Reduction of sildenafil dosage should be considered. [0m[1;31m([0m[31mSee Viagra package [0m
[31minsert. ERYTHROMYCIN ETHYLSUCCINATE: precautions: There have been spontaneous or published reports of CYP3A based interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil,[0m
[31mdisopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine, and bromocriptine. Concomitant administration of erythromycin with cisapride, pimozide, astemizole, or terfenadine is [0m
[31mcontraindicated. [0m[1;31m([0m[31mSee CONTRAINDICATIONS .[0m[1;31m)[0m[31m In addition, there have been reports of interactions of erythromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, [0m
[31mand valproate. ERYTHROMYCIN ETHYLSUCCINATE: precautions: Erythromycin has been reported to significantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken [0m
[31mconcomitantly. Rare cases of serious cardiovascular adverse events, including electrocardiographic QT/QT c interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias[0m
[31mhave been observed. [0m[1;31m([0m[31mSee CONTRAINDICATIONS .[0m[1;31m)[0m[31m In addition, deaths have been reported rarely with concomitant administration of terfenadine and erythromycin. There have been post-marketing reports of [0m
[31mdrug interactions when erythromycin was co-administered with cisapride, resulting in QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, and torsades de pointes [0m
[31mmost likely due to the inhibition of hepatic metabolism of cisapride by erythromycin. Fatalities have been reported.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m


[31mCONTENT: ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: Drug Interactions Theophylline Erythromycin use in patients who are receiving high doses of theophylline may be associated with an increase in [0m
[31mserum theophylline levels and potential theophylline toxicity. In case of theophylline toxicity and/or elevated serum theophylline levels, the dose of theophylline should be reduced while the patient [0m
[31mis receiving concomitant erythromycin therapy. There have been published reports suggesting that when oral erythromycin is given concurrently with theophylline there is a decrease in erythromycin [0m
[31mserum concentrations of approximately [0m[1;31m35[0m[31m%. The mechanism by which this interaction occurs is unknown. The decrease in erythromycin concentrations due to co-administration of theophylline could result [0m
[31min subtherapeutic concentrations of erythromycin. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: Hypotension, bradyarrhythmias, and lactic acidosis have been observed in patients receiving concurrent[0m
[31mverapamil, belonging to the calcium channel blockers drug class. Concomitant administration of erythromycin and digoxin has been reported to result in elevated digoxin serum levels. There have been [0m
[31mreports of increased anticoagulant effects when erythromycin and oral anticoagulants were used concomitantly. Increased anticoagulation effects due to interactions of erythromycin with various oral [0m
[31manticoagulants may be more pronounced in the elderly. Erythromycin is a substrate and inhibitor of the 3A isoform subfamily of the cytochrome p450 enzyme system [0m[1;31m([0m[31mCYP3A[0m[1;31m)[0m[31m. ERYTHROMYCIN ETHYLSUCCINATE: [0m
[31mdrug_interactions: Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the [0m
[31mtherapeutic and adverse effects of the concomitant drug. Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored [0m
[31mclosely in patients concurrently receiving erythromycin. The following are examples of some clinically significant CYP3A based drug interactions. Interactions with other drugs metabolized by the CYP3A[0m
[31misoform are also possible. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: The following CYP3A based drug interactions have been observed with erythromycin products in post-marketing experience: [0m
[31mErgotamine/dihydroergotamine Post-marketing reports indicate that co-administration of erythromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterized by [0m
[31mvasospasm and ischemia of the extremities and other tissues including the central nervous system. Concomitant administration of erythromycin with ergotamine or dihydroergotamine is contraindicated [0m
[1;31m([0m[31msee CONTRAINDICATIONS [0m[1;31m)[0m[31m. Triazolobenzodiazepines [0m[1;31m([0m[31msuch as triazolam and alprazolam[0m[1;31m)[0m[31m and Related Benzodiazepines Erythromycin has been reported to decrease the clearance of triazolam and midazolam, [0m
[31mand thus, may increase the pharmacologic effect of these benzodiazepines. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: HMG-CoA Reductase Inhibitors Erythromycin has been reported to increase [0m
[31mconcentrations of HMG-CoA reductase inhibitors [0m[1;31m([0m[31me.g., lovastatin and simvastatin[0m[1;31m)[0m[31m. Rare reports of rhabdomyolysis have been reported in patients taking these drugs concomitantly. Sildenafil [0m[1;31m([0m[31mViagra[0m[1;31m)[0m[31m [0m
[31mErythromycin has been reported to increase the systemic exposure [0m[1;31m([0m[31mAUC[0m[1;31m)[0m[31m of sildenafil. Reduction of sildenafil dosage should be considered. [0m[1;31m([0m[31mSee Viagra package insert.[0m[1;31m)[0m[31m There have been spontaneous or [0m
[31mpublished reports of CYP3A based interactions of erythromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine,[0m
[31mand bromocriptine. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: Concomitant administration of erythromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated. [0m[1;31m([0m[31mSee [0m
[31mCONTRAINDICATIONS .[0m[1;31m)[0m[31m In addition, there have been reports of interactions of erythromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate. [0m
[31mErythromycin has been reported to significantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken concomitantly. Rare cases of serious cardiovascular adverse[0m
[31mevents, including electrocardiographic QT/QT c interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias have been observed. [0m[1;31m([0m[31mSee CONTRAINDICATIONS .[0m[1;31m)[0m[31m In addition, [0m
[31mdeaths have been reported rarely with concomitant administration of terfenadine and erythromycin. ERYTHROMYCIN ETHYLSUCCINATE: drug_interactions: There have been post-marketing reports of drug [0m
[31minteractions when erythromycin was co-administered with cisapride, resulting in QT prolongation, cardiac arrhythmias, ventricular tachycardia, ventricular fibrillation, and torsades de pointes most [0m
[31mlikely due to the inhibition of hepatic metabolism of cisapride by erythromycin. Fatalities have been reported. [0m[1;31m([0m[31mSee CONTRAINDICATIONS .[0m[1;31m)[0m[31m Colchicine Colchicine is a substrate for both CYP3A4 and the [0m
[31mefflux transporter P-glycoprotein [0m[1;31m([0m[31mP-gp[0m[1;31m)[0m[31m. Erythromycin is considered a moderate inhibitor of CYP3A4. A significant increase in colchicine plasma concentration is anticipated when co-administered with [0m
[31mmoderate CYP3A4 inhibitors such as erythromycin.         [0m
[31mSOUR[0m[1;31mCE:E[0m[31mRYTHROMYCIN ETHYLSUCCINATE label[0m

 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the ERYTHROMYCIN ETHYLSUCCINATE label does not directly address the risk of myocardial infarction. However, it does mention that erythromycin can significantly [0m
[32malter the metabolism of certain drugs, leading to serious cardiovascular adverse events, including QT/QTc interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias.[0m
[32mThese events have been observed with the concomitant administration of erythromycin and certain other drugs, and in rare cases, deaths have been reported. While this does not specifically mention [0m
[32mmyocardial infarction, these cardiovascular events could potentially increase the risk of myocardial infarction.[0m

[32mSOURCE: ERYTHROMYCIN ETHYLSUCCINATE label[0m
[32mEXTRACT_START_END: Erythromycin has been reported[0m[32m...[0m[32m torsades de pointes most likely[0m[32m...[0m
*[1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the [0m
[34mERYTHROMYCIN ETHYLSUCCINATE label does not directly address the risk of myocardial infarction. However, it does mention that erythromycin can significantly alter the metabolism of certain drugs, [0m
[34mleading to serious cardiovascular adverse events, including QT/QTc interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias. These events have been observed with [0m
[34mthe concomitant administration of erythromycin and certain other drugs, and in rare cases, deaths have been reported. While this does not specifically mention myocardial infarction, these [0m
[34mcardiovascular events could potentially increase the risk of myocardial infarction.[0m

[34mSOURCE: ERYTHROMYCIN ETHYLSUCCINATE label[0m
[34mEXTRACT_START_END: Erythromycin has been reported[0m[34m...[0m[34m torsades de pointes most likely[0m[34m...[0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mThe FDA label for ERYTHROMYCIN ETHYLSUCCINATE [0m
[32mdoes not directly address the risk of myocardial infarction. However, it does mention that erythromycin can significantly alter the metabolism of certain drugs, which can lead to serious [0m
[32mcardiovascular adverse events. These events include QT/QTc interval prolongation, cardiac arrest, torsades de pointes, and other ventricular arrhythmias. In rare cases, deaths have been reported in [0m
[32massociation with these cardiovascular events when erythromycin is administered concomitantly with certain other drugs. While these cardiovascular events do not specifically mention myocardial [0m
[32minfarction, they could potentially increase the risk of myocardial infarction.[0m

[32mGiven the information provided, we cannot definitively say whether ERYTHROMYCIN ETHYLSUCCINATE increases or decreases the risk of myocardial infarction, as the label does not provide a direct [0m
[32mcorrelation. The cardiovascular events mentioned could potentially increase the risk, but this is not explicitly stated in the label. Therefore, the degree of reliability of this answer is limited to [0m
[32mthe information available from the label, which does not conclusively determine the effect of ERYTHROMYCIN ETHYLSUCCINATE on the risk of myocardial infarction.[0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m
*[1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m          [1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Do one of the following:[0m

[31m        [0m[1;31m1[0m[31m. If you intend to ask a question to FDAAgent:[0m
[31m            Please use the [0m[31m'add_recipient'[0m[31m tool/function-call[0m
[31m            and specify FDAAgent as your `intended_recipient`.[0m
[31m            DO NOT REPEAT your original message; ONLY specify the [0m
[31m            `intended_recipient` via this tool/function-call.[0m
[31m        [0m[1;31m2[0m[31m. If you are ready to have the critic check your answer,[0m
[31m            do so with the `final_answer` tool/function, as I have requested.[0m
[31m        [0m[1;31m3[0m[31m. If the critic is satisfied and you intend to submit your final answer,[0m
[31m            answer as I have requested, making sure to mark that you are done as usual.[0m

[31m        When you have decided and stated your answer [0m[1;31m([0m[31mor lack of one[0m[1;31m)[0m[31m, you must[0m
[31m        ALWAYS specify that you are done using the usual code.[0m

[31m        DO NOT simply acknowldedge these instructions. If you have nothing[0m
[31m        else to say, you MUST EXIT IMMEDIATELY by stating that you are done[0m
[31m        with the usual code [0m[1;31m([0m[31mas in #[0m[1;31m3[0m[1;31m)[0m[31m.[0m
[31m        [0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of myocardial infarction?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether ERYTHROMYCIN ETHYLSUCCINATE increases or decreases the risk of myocardial infarction."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the ERYTHROMYCIN ETHYLSUCCINATE label does not directly address the risk of myocardial infarction but mentions serious cardiovascular adverse events that could [0m
[32mpotentially increase the risk of myocardial infarction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of myocardial infarction?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether ERYTHROMYCIN ETHYLSUCCINATE increases or decreases the risk of myocardial infarction."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the ERYTHROMYCIN ETHYLSUCCINATE label does not directly address the risk of myocardial infarction but mentions serious cardiovascular adverse events that could [0m
[34mpotentially increase the risk of myocardial infarction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does ERYTHROMYCIN ETHYLSUCCINATE increase or decrease the risk of myocardial infarction?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether ERYTHROMYCIN ETHYLSUCCINATE increases or decreases the risk of myocardial infarction.[0m
[1;31m2[0m[31m. FDAHandler responded that the ERYTHROMYCIN ETHYLSUCCINATE label does not directly address the risk of myocardial infarction but mentions serious cardiovascular adverse events that could potentially[0m
[31mincrease the risk of myocardial infarction.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning process appears to be consistent with the guidelines provided. The user has asked FDAHandler about the effect of ERYTHROMYCIN ETHYLSUCCINATE on the risk of myocardial [0m
[32minfarction, and FDAHandler has indicated that the label does not directly address this risk but mentions serious cardiovascular adverse events. The user has appropriately concluded with a DO-NOT-KNOW [0m
[32manswer, as the information provided does not definitively establish an increase or decrease in risk. This conclusion is justified given the lack of direct evidence from the label and is in line with [0m
[32mthe instructions to accept DO-NOT-KNOW when the answer clearly expresses why it was not possible to answer the question."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning process appears to be consistent with the guidelines provided. The user has asked FDAHandler about the effect of ERYTHROMYCIN ETHYLSUCCINATE on the risk of myocardial [0m
[34minfarction, and FDAHandler has indicated that the label does not directly address this risk but mentions serious cardiovascular adverse events. The user has appropriately concluded with a DO-NOT-KNOW [0m
[34manswer, as the information provided does not definitively establish an increase or decrease in risk. This conclusion is justified given the lack of direct evidence from the label and is in line with [0m
[34mthe instructions to accept DO-NOT-KNOW when the answer clearly expresses why it was not possible to answer the question."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning process appears to be consistent with the guidelines provided. The user has asked FDAHandler about the effect of ERYTHROMYCIN ETHYLSUCCINATE on the risk of myocardial [0m
[31minfarction, and FDAHandler has indicated that the label does not directly address this risk but mentions serious cardiovascular adverse events. The user has appropriately concluded with a DO-NOT-KNOW [0m
[31manswer, as the information provided does not definitively establish an increase or decrease in risk. This conclusion is justified given the lack of direct evidence from the label and is in line with [0m
[31mthe instructions to accept DO-NOT-KNOW when the answer clearly expresses why it was not possible to answer the question.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-myocardial infarction-ERYTHROMYCIN ETHYLSUCCINATE[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe FDA label for ERYTHROMYCIN ETHYLSUCCINATE does not provide direct information on whether it increases or decreases the risk of myocardial infarction. The label does mention serious cardiovascular [0m
[32madverse events that could potentially increase the risk of myocardial infarction, but there is no explicit statement connecting ERYTHROMYCIN ETHYLSUCCINATE to an increased or decreased risk of [0m
[32mmyocardial infarction. Therefore, based on the available FDA label data, we cannot determine the effect of ERYTHROMYCIN ETHYLSUCCINATE on the risk of myocardial infarction.[0m
